PRIMARY STUDY
Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial
Key Findings: In subjects with chronic kidney disease (CKD), compared to the nonprogression group the urinary L-FABP level was significantly higher in the progression group, suggesting it is more sensitive than urinary protein in predicting the progression of CKD.
Type of Study: Clinical Trial
Study Sample Size: 48
Study Result: Positive
Research Location(s): Japan
Year of Pub: 2005
Cannabinoids Studied: Fatty Acid-Binding Protein (FABP)
Phytocannabinoid Source: Not Applicable
Citation: Kamijo A, et al. Clinical evaluation of urinary excretion of liver-type fatty acid-binding protein as a marker for the monitoring of chronic kidney disease: a multicenter trial. J Lab Clin Med. 2005; 145:125-33. doi: 10.1016/j.lab.2004.12.003
Authors: Kamijo A, Sugaya T, Hikawa A, Yamanouchi M, Hirata Y, Ishimitsu T, Numabe A, Takagi M, Hayakawa H, Tabei F, Sugimoto T, Mise N, Kimura K
